Mesenchymal Stem Cells Co-transplantation in Alternative Donor Transplantation of Severe Aplastic Anemia.
NCT02247973 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2014-09-25
Summary
The study is a phase II trial designed to evaluate the efficacy and safety of co-transplantation with bone marrow derived mesenchymal stem cells from related donors in alternative donor transplantation of severe aplastic anemia.
Conditions
- Severe Aplastic Anemia
Interventions
- BIOLOGICAL
-
mesenchymal stem cells
Intravenous administration of up to 1\~2x10\^6 MSCs per kg,for 2 times,d0 and d14
- BIOLOGICAL
-
mesenchymal stem cells
bone marrow derived mesenchymal stem cells from related donors.
Sponsors & Collaborators
-
Guangzhou First People's Hospital
collaborator OTHER -
Nanfang Hospital, Southern Medical University
collaborator OTHER -
Southern Medical University, China
collaborator OTHER -
First Affiliated Hospital, Sun Yat-Sen University
collaborator OTHER -
Second Affiliated Hospital, Sun Yat-Sen University
collaborator OTHER -
Third Affiliated Hospital, Sun Yat-Sen University
collaborator OTHER -
Fifth Affiliated Hospital, Sun Yat-Sen University
collaborator OTHER -
Guangdong Provincial People's Hospital
collaborator OTHER -
The Second People's Hospital of GuangDong Province
collaborator OTHER -
First Affiliated Hospital of Jinan University
collaborator OTHER -
The First Affiliated Hospital of Guangzhou Medical University
collaborator OTHER -
Second Affiliated Hospital of Guangzhou Medical University
collaborator OTHER -
Peking University Shenzhen Hospital
collaborator OTHER -
Shenzhen Second People's Hospital
collaborator OTHER -
Guangzhou General Hospital of Guangzhou Military Command
lead OTHER
Principal Investigators
-
Yang Xiao, MD · Guangzhou General Hospital of Guangzhou Military Command
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 14 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-02-28
- Primary Completion
- 2017-02-28
- Completion
- 2018-02-28
Countries
- China
Study Locations
More Related Trials
-
Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia
NCT06378060 ·Status: RECRUITING ·Phase: PHASE2
-
Co-transplantation of MSC in the Setting of Allo-HSCT
NCT04247945 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy
NCT02559830 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function
NCT02083718 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT
NCT04738981 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of BM-MSCs in DCD Kidney Transplantation
NCT02561767 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells
NCT02291770 ·Status: UNKNOWN ·Phase: PHASE3
-
MSC for Treatment of cGVHD After Allo-HSCT
NCT04692376 ·Status: UNKNOWN ·Phase: PHASE2
-
Mesenchymal Stem Cells for the Treatment of Pneumonia Post Haematopoietic Stem Cell Transplantation
NCT05131412 ·Status: COMPLETED
-
Induction Therapy With Autologous Mesenchymal Stem Cells for Kidney Allografts
NCT00658073 ·Status: COMPLETED ·Phase: NA
-
Modified Transplantation Regimen and aGVHD Prophylaxis for Severe Aplastic Anemia in the Setting of Allogeneic HSCT.
NCT06837987 ·Status: COMPLETED
-
Allogenic Bone Marrow Stem Cell Transplantation in Liver Failure
NCT01221454 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Chronic Graft Versus Host Disease
NCT01526850 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT
NCT05290545 ·Status: COMPLETED ·Phase: PHASE3
-
MSC for Treatment of Interstitial Lung Disease After Allo-HSCT
NCT02543073 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Clinical Study on the Impact of Covid-19 Vaccine on Allogeneic Hematopoietic Stem Cell Transplantation
NCT05587881 ·Status: WITHDRAWN
-
Effect of BM-MSCs on Chronic AMR After Kidney Transplantation
NCT02563340 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Musculoskeletal Outcomes After Bone Marrow Transplant
NCT00558948 ·Status: COMPLETED
-
Allogeneic Bone Marrow Mesenchymal Stem Cells Transplantation in Patients With Liver Failure Caused by Hepatitis B Virus (HBV)
NCT01322906 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia
NCT05776173 ·Status: RECRUITING ·Phase: NA
-
Comparison of Peripheral Blood Stem Cell Transplantation With Bone Marrow Transplantation for the Treatment of Serious Hematological Malignancies
NCT00275678 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells
NCT04211480 ·Status: COMPLETED ·Phase: NA
-
MSC for Severe aGVHD
NCT03631589 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Allogeneic Hematopoietic Stem Cell Transplantation Cohort Study
NCT06708130 ·Status: RECRUITING
-
Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies
NCT02179359 ·Status: TERMINATED ·Phase: NA